1. Executive Summary
1.1 Overview
1.2 Review of the Vaccine Manufacturing Technology and Services Market
1.3 Aims, Scope and Format of Report
1.4 Research and Analysis Methods
2. Introduction to Vaccines
2.1 The History of Vaccines
2.2 How do Vaccines Work?
2.2.1 Artificial Immunity
2.3 Types of Vaccine
2.3.1 Live, Attenuated Vaccines
2.3.2 Recombinant Live Vaccines
2.3.3 Inactivated Vaccines
2.3.4 Toxoid Vaccines
2.3.5 Subunit Vaccines
2.3.6 Conjugate Vaccines
2.3.7 Recombinant Subunit Vaccines
2.3.8 DNA Vaccines
2.3.9 Recombinant Vector Vaccines
2.3.10 Therapeutic Vaccines
2.4 Diseases Preventable with Vaccines
2.5 The Rise of the Vaccines Market
2.6 Technological and Regulatory Improvements
3. Vaccine Manufacturing Technologies, 2013
3.1 Summary of Vaccine Technology Trends
3.2 New Substrates for Vaccine Production
3.2.1 Shift towards Cell-Based Manufacturing Technology
3.2.2 Benefits of Cell-Based Techniques
3.2.3 Mammalian Cell Lines
3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.2.3.2 Vero Cells
3.2.3.3 PerC6 Cells
3.2.4 Avian-Derived Cell Lines
3.2.4.1 EB66 Stem Cell Technology: Vivalis
3.2.5 Plant-Based Vaccines
3.2.5.1 Medicago's Proficia VLP Vaccine Technology
3.2.6 Insect Egg-Based Production Systems
3.2.6.1 Novavax
3.2.6.2 Protein Sciences Corporation (PSC)
3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.3.1 AdVac Technology: Crucell
3.3.2 AdCEV Vectors: AfriVax
3.3.3 Pfenex Expression Technology: Pfenex
3.4 Equipment Trends
3.4.1 The Shift Towards Disposable Single-use Equipment
3.4.2 Bioreactors and Vaccine Production
3.4.2.1 Single-Use Bioreactors
3.4.2.2 Main Applications of Disposable Bioreactors
3.4.2.3 Current Single-Use Bioreactor Systems on the Market
3.5 Prefilled Syringes and Vaccines
3.5.1 Growing Market for Pre-Filled Syringes
3.5.2 Leading Pre-Filled Vaccine Products 2012
3.5.3 Drivers and Restraints for Pre-filled Syringes
3.5.4 Product Stability and Quality Assurance Programme
3.5.4.1 Paediatric H1N1 Vaccine
3.5.4.2 Reported Challenges with Some Flu Vaccine
3.5.4.3 Reported Shelf Life Issues of Some H1N1 Vaccine
3.6 Lyophilisation and Vaccine Manufacturing
3.6.1 Lyophilisation of Vaccines will Increase
3.6.2 Commercial Drivers of Lyophilisation
3.6.3 Commercial Restraints for the Lyophilisation Technology Market
3.6.3.1 High Entry Barriers to Sector
3.7 Cell Media Can Improve Virus Yield
4. The Global Vaccine Manufacturing Market 2013-2023
4.1 Overview of the Global Vaccine Manufacturing Market 2013-2023
4.2 World Vaccine Market Forecast 2013-2023
4.3 Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
4.4 Paediatric Vaccines Market Overview
4.4.1 Paediatric Vaccines Market Forecast 2013-2023
4.5 Adult Prophylactic Vaccines Market Overview
4.5.1 Adult Prophylactic Vaccines Market Forecast 2013-2023
4.6 Influenza Vaccines Market Overview
4.6.1 Influenza Vaccines Market Forecast 2013-2023
4.7 Therapeutic Vaccines Market Overview
4.7.1 Therapeutic Vaccines Market Forecast 2013-2023
4.8 Leading Companies in the Vaccine Manufacturing Market 2012
4.8.1 GlaxoSmithKline
4.8.2 Sanofi Pasteur
4.8.3 Pfizer
4.8.4 Merck
4.8.5 Novartis
4.8.6 Other Vaccine Manufacturers
5. Outsourcing Vaccine Manufacturing 2013-2023
5.1 Outsourcing in the Pharmaceutical and Biotechnology Industry
5.1.1 Reasons to Outsource
5.1.2 Benefits of Outsourcing
5.1.3 The Challenges in Outsourcing Vaccine Manufacturing
5.1.4 Why Should Companies Outsource Vaccine Manufacturing?
5.1.5 Strategic Outsourcing vs. Tactical Outsourcing
5.1.6 Virtual Companies
5.2 Contract Manufacturing Organisations (CMOs)
5.2.1 Manufacturing Services Offered by CMOs
5.2.2 Vaccine Manufacturing Activities Typically Outsourced
5.3 The Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast 2013-2023
5.4 Contract Manufacturing Market for Vaccines 2013-2023
5.4.1 Market Size for Contract Manufacturing of Vaccines 2011
5.4.2 Vaccine Contract Manufacturing Market Forecast 2013-2023
5.5 Leading Vaccine Contract Manufacturing Organisations
5.5.1 Baxter BioPharma Solutions
5.5.2 Boehringer Ingelheim
5.5.2.1 Recent Financial Performance
5.5.2.2 Ben Venue Laboratories
5.5.2.3 Manufacturing Deals 2011-2012
5.5.2.4 Outlook
5.5.3 Catalent
5.5.3.1 Recent Financial Performance
5.5.3.2 Strong Growth for Oral Delivery Technologies
5.5.3.3 Catalent Injectable Vaccines
5.5.3.4 Catalent Adjusts its Services
5.5.3.5 Outlook
5.5.4 Charles River Laboratories
5.5.4.1 Revenue Analysis 2006-2011
5.5.4.2 Vaccine Manufacturing Services
5.5.4.3 Charles River Avian Vaccine Services
5.5.4.4 Outlook and Early Stage Restructuring
5.5.5 IDT Biologika GmbH
5.5.6 Lonza
5.5.6.1 Recent Financial Performance
5.5.6.2 Lonza: Biologics and Vaccines
5.5.6.3 Outlook
5.5.7 Meridian Life Science
5.5.7.1Revenue Analysis
5.5.8 SAFC (Sigma-Aldrich Fine Chemicals)
5.5.8.1 SAFC Revenue Analysis
5.5.9 SynCo Bio Partners
6. Leading National Markets 2013-2023
6.1 The US, Europe and Japan are the Largest Markets for Vaccines
6.2 The US Vaccine Market Forecast 2013-2023
6.2.1 The US National Vaccination Plan
6.2.2 Challenges in the US Vaccines Market
6.2.3 CMO Services in the US
6.3 The EU5 Vaccine Market Forecast 2013-2023
6.3.1 The EU5: Trends in CMO Services for Vaccine Manufacturing
6.3.2 The German Vaccine Market Forecast 2013-2023
6.3.3 The French Vaccine Market Forecast 2013-2023
6.3.4 The UK Vaccine Market Forecast 2013-2023
6.3.5 The Spanish Vaccine Market Forecast 2013-2023
6.3.6 The Italian Vaccine Market Forecast 2013-2023
6.4 The Japanese Vaccine Market
6.4.1 The Japanese Vaccine Market Forecast 2013-2023
6.4.2 CMOs in Japan
6.5 BRIC Nations: Market Overview
6.5.1 BRIC Nations: Vaccines Market Forecast 2013-2023
6.5.2 The Brazilian Vaccine Market Forecast 2013-2023
6.5.3 The Russian Vaccine Market Forecast 2013-2023
6.5.4 The Indian Vaccine Market Forecast 2013-2023
6.5.5 The Chinese Vaccine Market Forecast 2013-2023
7. Vaccine Manufacturing Market: World Market Trends 2013-2023
7.1 SWOT Analysis of the Market 2013-2023
7.2 The Strengths of the Global Vaccine Manufacturing Market
7.2.1 Vaccines are a Healthcare Success
7.2.2 Blockbuster Vaccines
7.2.3 Low Generic Competition
7.3 Weaknesses of the Global Vaccine Manufacturing Market
7.3.1 Entry Barriers are High
7.3.2 Unpredictable Demand for Vaccines
7.3.3 High Costs and Complex Manufacturing Processes
7.3.4 Limitations of the Production Facility: Difficult Product Changeover
7.4 Opportunities for Vaccine Manufacturers
7.4.1 Vaccine Manufacturers Expand into New Indications
7.4.2 Bioterrorism
7.4.3 Pandemic Preparedness
7.4.4 Outsourcing Vaccine Manufacturing
7.4.5 Changing World Demographics
7.5 Threats in the Vaccine Manufacturing Market
7.5.1 Storage and Supply Difficulties for Vaccine Distribution Networks
7.5.2 Threat to Vaccine Prices
7.5.3 Consolidation of Vaccine Manufacturers
7.6 STEP Analysis: Vaccine Manufacturing Market 2013-2023
7.6.1 Social
7.6.1.1 The Controversy Surrounding Vaccines
7.6.1.2 Lack of Public Education Regarding Vaccines
7.6.2 Technological
7.6.2.1 New Types of Vaccines
7.6.2.2 Personalised Vaccines
7.6.2.3 New Adjuvants for Vaccines
7.6.2.4 New Vaccine Delivery Mechanisms and Formulations
7.6.3 Economic
7.6.3.1 Growth of the Emerging Economies
7.6.4 Political
7.6.4.1 Vaccines in National and International Policy
7.6.4.2 Government Preparedness and Protection
8. Opinions from Our Survey
8.1 Interview with Richard van Rijnsoever, Director, Business Development, SynCo Bio Partners
8.1.1 Thoughts on Contract Manufacturing for Vaccines
8.1.2 Vaccine Services and Their Benefits
8.1.3 Impact of New Technology on Vaccine Manufacturing
8.1.4 Trends in Emerging Markets
8.2 Interview with Dr Louis Picker, Associate Director of OHSU's Vaccine and Gene Therapy Institute
8.2.1 The Basic Challenge of Developing a HIV Vaccine
8.2.2 Early Interception of HIV Infections via Antibodies
8.2.3 Early Interception of HIV Infections via T-Cells
8.2.4 The Use of CMV as a Vaccine Vector
8.2.5 The Effectiveness of the Vaccine in Humans
8.2.6 The Pre-Exposure Prophylactic Use of Anti-Retroviral Drugs as an Alternative Strategy
8.2.7 The Timeline for a Human Trial of the Vaccine
9. Conclusions
9.1 Vaccines Market Will Continue to Expand
9.2 Paediatric Vaccines Sector will Continue to Dominate
9.3 The Emerging Markets Gain Importance
9.4 Technology Drives Changes in Manufacturing
9.5 Outsourcing Vaccine Manufacturing Will Increase
List of Tables
Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD-Present
Table 3.1 Vaccine Development Pipeline using Protein Sciences Corporation's BEVS Vaccine Technology, 2012
Table 3.2 Vaccine Development Pipeline Using Crucell's AdVac Technology, 2012
Table 3.3 Benefits and Drawbacks of Using Disposable Technology for Vaccine Production, 2012
Table 3.4 Companies Providing Disposable Biomanufacturing Platforms/Systems, 2011
Table 3.5 Some Leading Pre-Filled Syringe Vaccine Products, 2012
Table 3.6 Prominent Lyophilised Vaccines, 2012
Table 3.7 Examples Serum-free Media for Vaccines Manufacturing, 2012
Table 4.1 Sectors within the Vaccines Market: Description, Sales ($bn), Market Shares (%), 2011
Table 4.2 Global Vaccine Manufacturing Revenue Forecasts - Overall Market and Submarkets ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.3 Global Vaccine Manufacturing Revenue Forecasts - Overall Market and Submarkets ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.4 Global Vaccine Manufacturing: World Market Shares by Region (%), 2011, 2017 & 2023
Table 4.5 Paediatric Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.6 Paediatric Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.7 Adult Prophylactic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.8 Adult Prophylactic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.9 Influenza Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.10 Influenza Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.11 Therapeutic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 4.12 Therapeutic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.13 Leading Companies in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011
Table 5.1 Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast, ($bn), AGR (%), CAGR (%), 2011-2017
Table 5.2 Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast, ($bn), AGR (%), CAGR (%), 2017-2023
Table 5.3 Vaccine Contract Manufacturing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.4 Vaccine Contract Manufacturing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.5 Prominent Vaccine Contract Manufacturing Organisations, 2012
Table 5.6 Baxter BioPharma Solutions Capabilities, 2012
Table 5.7 Boehringer Ingelheim: Contract Manufacturing Revenue ($bn) by Division, 2009-2011
Table 5.8 Catalent: Revenue ($bn) by Division, 2009-2011
Table 5.9 Selected Services Provided by Charles River Laboratories, 2012
Table 5.10 Charles River Laboratories Revenue ($bn), 2006-2011
Table 5.11 Charles River Laboratories Revenue ($bn) by Business Segment, 2009-2011
Table 5.12 Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities, 2012
Table 5.13 Lonza: Custom Manufacturing Revenue ($bn), 2009-2011
Table 5.14 Meridian Bioscience & Meridian Life Science: Revenue ($m), 2009-2012
Table 5.15 SAFC Revenue ($m), AGR (%), 2007-2011
Table 5.16 SynCo Bio Partners Capabilities, 2012
Table 6.1 Leading National Vaccine Manufacturing Technology and Services Revenue Forecasts ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.2 Leading National Vaccine Manufacturing Technology and Services Revenue Forecasts ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.3 Vaccine Manufacturing Technology and Services: World Market Shares by Region (%), 2011, 2017 & 2023
Table 6.4 The US Drug Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.5 The US Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.6 EU5 Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.7 EU5 Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.8 Vaccine Manufacturing Technology and Services: EU5 Market Shares by Region (%), 2011, 2017 & 2023
Table 6.9 The German Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.10 The German Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.11 The French Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.12 The French Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.13 The UK Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.14 The UK Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.15 The Spanish Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.16 The Spanish Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.17 The Italian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.18 The Italian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.19 The Japanese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.20 The Japanese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.21 BRIC Nations: Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.22 BRIC Nations: Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.23 Vaccine Manufacturing Technology and Services: BRIC Market Shares by Region (%), 2011, 2017 & 2023
Table 6.24 The Brazilian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.25 The Brazilian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.26 The Russian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.27 The Russian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.28 The Indian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.29 The Indian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.30 The Chinese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017
Table 6.31 The Chinese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023
Table 7.1 SWOT Analysis for the Global Vaccine Manufacturing Sector, 2013-2023
List of Figures
Figure 3.1 Influenza Vaccine Production Using a Cell-Based Manufacturing Method, 2012
Figure 3.2 Novavax' Insect Egg-Based Vaccine Production Process, 2012
Figure 3.3 Worldwide Single-Use Systems Market, 2011
Figure 3.4 Pre-filled Syringes Market: Drivers and Restraints, 2013-2023
Figure 3.5 Lyophilisation Market: Drivers and Restraints, 2013-2023
Figure 4.1 Global Vaccine Manufacturing Forecast ($bn), 2011-2023
Figure 4.2 Global Vaccine Manufacturing: World Market Shares by Region (%), 2011
Figure 4.3 Global Vaccine Manufacturing: World Market Shares by Region (%), 2017
Figure 4.4 Global Vaccine Manufacturing: World Market Shares by Region (%), 2023
Figure 4.5 Paediatric Vaccine Manufacturing Forecast ($bn), 2011-2023
Figure 4.6 Adult Prophylactic Vaccine Manufacturing Forecast ($bn), 2011-2023
Figure 4.7 Influenza Vaccine Manufacturing Forecast ($bn), 2011-2023
Figure 4.8 Therapeutic Vaccine Manufacturing Forecast ($bn), 2011-2023
Figure 4.9 Leading Companies in the Vaccines Market: Overall Market Shares (%), 2011
Figure 5.1 Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry, 2012
Figure 5.2 Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast, ($bn), 2011-2023
Figure 5.3 Vaccine Contract Manufacturing Forecast ($m), 2011-2023
Figure 5.4 Boehringer Ingelheim: Contract Manufacturing Revenue ($bn) by Division, 2009-2011
Figure 5.5 Boehringer Ingelheim: Typical Contract Manufacturing Process, 2012
Figure 5.6 Catalent: Revenue Shares (%) by Division, 2011
Figure 5.7 Charles River Laboratories Revenue ($bn), 2006-2011
Figure 5.8 Charles River Laboratories Revenue Shares (%) by Business Segment, 2011
Figure 5.9 Charles River Laboratories: Vaccine Development and Commercialisation Services, 2012
Figure 5.10 Lonza: Custom Manufacturing Revenue ($bn), 2009-2011
Figure 5.11 Meridian Bioscience & Meridian Life Science: Revenue ($m), 2009-2012
Figure 5.12 SAFC Vaccine Manufacturing Services, 2012
Figure 5.13 SAFC Revenue ($m), 2007-2011
Figure 6.1 Vaccine Manufacturing Technology and Services: World Market Shares by Region (%), 2011
Figure 6.2 Vaccine Manufacturing Technology and Services: World Market Shares by Region (%), 2017
Figure 6.3 Vaccine Manufacturing Technology and Services: World Market Shares by Region (%), 2023
Figure 6.4 The US Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 6.5 The EU5 Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 6.6 Vaccine Manufacturing Technology and Services: EU5 Market Shares by Region (%), 2011
Figure 6.7 The German Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 6.8 The French Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 6.9 The UK Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 6.10 The Spanish Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 6.11 The Italian Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 6.12 The Japanese Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 6.13 BRIC Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 6.14 Vaccine Manufacturing Technology and Services: BRIC Market Shares by Region (%), 2011
Figure 6.15 The Brazilian Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 6.16 The Russian Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 6.17 The Indian Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 6.18 The Chinese Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023
Figure 7.1 Drivers and Restraints for the Outsourcing Vaccine Manufacturing Sector, 2013-2023